BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  Vaccine Manufacturers Practicing for Worse COVID-19 Variants to Emerge

  Winter is quickly approaching in the U.S. Vaccine makers aren’t taking a wait-and-see approach but actively preparing for what may come next.

  October 21, 2021

   · 

  3 min read

   · 

  Kate Goodwin
• 

  Business

  BioSpace Movers & Shakers, Oct. 22

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

  October 21, 2021

   · 

  10 min read

   · 

  Alex Keown
• 

  Business

  Pfizer COVID Vaccine Contributor Saama Lands $430 Million Investment

  Saama Technologies secured a $430 million investment from the Carlyle Group and venture funds from some of the pharmaceutical industry’s biggest companies.

  October 21, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Intellia’s Milestone In Vivo CRISPR Therapy Granted FDA Orphan Drug Designation

  The experimental drug, NTLA-2001, is being developed for the treatment of transthyretin (ATTR) amyloidosis.

  October 21, 2021

   · 

  3 min read

   · 

  Heather McKenzie
• 

  Biotech Bay

  ReCode Scores $80 Million to Advance mRNA-Based Cystic Fibrosis, PCD Programs

  ReCode is aiming to advance its lead candidates for cystic fibrosis and primary ciliary dyskinesia (PCD).

  October 21, 2021

   · 

  4 min read

   · 

  Alex Keown
• 

  FDA

  FDA Signs Off on Moderna, J&J Boosters and Mixed Doses

  The U.S. FDA approved the use of Moderna’s and Janssen’s COVID-19 vaccines as a booster dose after their primary versions are completed.

  October 21, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Policy

  COVID Update: New Delta Subtype Rising and Ivermectin Continues to Cause Problems

  A subtype of the Delta variant might be rising, although it’s not yet clear if it’s more transmissible or lethal than the original Delta variant. Read on for that and more COVID-19 news.

  October 21, 2021

   · 

  4 min read

   · 

  Mark Terry
• 

  BioMidwest

  Research Roundup: Regrowing Nerve Cells in Spinal Cord Injuries and More

  Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

  October 21, 2021

   · 

  5 min read

   · 

  Mark Terry
• 

  Deals

  Two Biopharmas Nix IPO Plans in Unstable Market

  Numerous biopharma and life sciences companies have sought to put their stocks up for sale, but this week, two companies opted to pull out their IPO due to concerns over market stability.

  October 21, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Pharm Country

  Three Studies Validate Effectiveness of Pfizer-BioNTech Vaccine, Booster

  The Pfizer-BioNTech mRNA COVID-19 vaccine is reportedly the top vaccine used globally. Here’s a look at today’s highlights.

  October 21, 2021

   · 

  3 min read

   · 

  Mark Terry